# EDGAR Filing Document

**Accession Number:** 0001412486
**File Stem:** 0001641172-25-027234
**Filing Date:** 2025-9
**Character Count:** 2237
**Document Hash:** bd7367c3066242d7dfcbf6c61862c11d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-027234.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0001641172-25-027234

**CONFORMED SUBMISSION TYPE**: 424B3

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250912

**DATE AS OF CHANGE**: 20250912

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cocrystal Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001412486
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 352528215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-271883
- **FILM NUMBER:** 251312413

**BUSINESS ADDRESS:**
- **STREET 1:** 19805 N. CREEK PARKWAY
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98011
- **BUSINESS PHONE:** (786) 459-1831

**MAIL ADDRESS:**
- **STREET 1:** 19805 N. CREEK PARKWAY
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIOZONE PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20110304

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** International Surf Resorts, Inc.
- **DATE OF NAME CHANGE:** 20070917

**Filed pursuant to Rule 424(b)(3)**

**Registration No. 333-271883**

---

| |
|:---|
| **PROSPECTUS SUPPLEMENT** |
| **(To the Prospectus dated May 24, 2023)** |

---

This prospectus supplement supplements and amends certain information contained in the prospectus supplement dated June 15, 2023. Prior to 9:30 a.m., Eastern Time on September 12, 2025. Cocrystal Pharma, Inc. (the "Company") and H.C. Wainwright & Co., LLC agreed to terminate the sales of shares of the Company's common stock under that certain At-The-Market Offering Agreement dated July 1, 2020, as amended (the "Sales Agreement"). As a result of this, the at-the-market offering under the Sales Agreement is no longer ongoing as of September 12, 2025 and we will not make any sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission; however, the Sales Agreement remains in full force and effect.

**PROSPECTUS SUPPLEMENT**

**H.C. Wainwright & Co.**

September 12, 2025